Kyowa Kirin Co., Ltd. (TYO:4151)
Japan · Delayed Price · Currency is JPY 2,514.50
+18.50 (0.74%)
Apr 15, 2026, 11:30 AM JST
Kyowa Kirin Employees
Kyowa Kirin had 5,161 employees as of December 31, 2025. The number of employees decreased by 508 or -8.96% compared to the previous year.
Employees
5,161
Change (1Y)
-508
Growth (1Y)
-8.96%
Revenue / Employee
96.27M JPY
Profits / Employee
12.99M JPY
Market Cap
1.31T
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5,161 | -508 | -8.96% |
| Dec 31, 2024 | 5,669 | -305 | -5.11% |
| Dec 31, 2023 | 5,974 | 222 | 3.86% |
| Dec 31, 2021 | 5,752 | 329 | 6.07% |
| Dec 31, 2020 | 5,423 | 156 | 2.96% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Otsuka Holdings | 37,758 |
| Daiichi Sankyo Company | 19,765 |
| Astellas Pharma | 13,643 |
| Chugai Pharmaceutical | 5,104 |
| Ono Pharmaceutical | 4,287 |
| Santen Pharmaceutical | 3,849 |
| JCR Pharmaceuticals | 987 |
| Perseus Proteomics | 32 |
Kyowa Kirin News
- 6 weeks ago - Kyowa Kirin stops development of skin condition treatment - Reuters
- 2 months ago - Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends - Benzinga
- 4 months ago - Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman - Business Wire
- 5 months ago - Kyowa Kirin to Present New Research Highlighting Mogamulizumab's Clinical Utility and Strategic Potential in T-Cell Lymphomas at 2025 ASH Annual Meeting - GlobeNewsWire
- 5 months ago - Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region - Business Wire
- 5 months ago - Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a novel treatment for patients with autoimmune diseases - GlobeNewsWire
- 6 months ago - Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan - GlobeNewsWire
- 8 months ago - Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers - GlobeNewsWire